Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Obesity | Research

Clinical characteristics and therapeutic response of differentiated thyroid carcinoma with obesity and diabetes

Authors: Xuan Wang, Yang Yu, Yanhui Ji, Ziyu Ma, Jian Tan, Qiang Jia, Ning Li, Wei Zheng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The effects of obesity and diabetes on the clinical outcomes of differentiated thyroid cancer (DTC) remain unclear.

Objectives

To explore the association between obesity and diabetes with pathological features and therapeutic response of DTC.

Methods

Patients were categorized based on body mass index (BMI) and glycemic status. Compare the correlation between BMI and glycemic status with pathological features and therapeutic response of DTC. To analyze the independent risk factors for the aggressiveness of DTC.

Results

The proportion of patients with bilateral tumors was higher in the overweight, obese and diabetes group (P = 0.001, 0.045). The overweight group demonstrated a higher TNM stage (P = 0.004), while the T and TNM stages were higher in the diabetes group (P = 0.032, 0.000). The probability of distant metastasis increases by 37.4% for each unit of BMI increase (odds ratio (OR) = 1.374, CI 95% 1.061–1.778, P < 0.05). The BMI of Biochemical Incomplete Response (BIR) is significantly higher than that of Excellent Response (ER) (P = 0.015), the fasting plasma glucose (FPG) of Structural Incomplete (SIR) was significantly higher than that of ER and BIR (P = 0.030, 0.014).

Conclusion

Obesity and diabetes have effect on DTC aggressiveness. BMI and FPG have correlation with the therapeutic response of DTC patients.
Literature
1.
Mansour J, Sagiv D, Alon E, Talmi Y. Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma. J Laryngol Otol. 2017;132(1):8–13. CrossRefPubMed
2.
Pagano L, Mele C, Arpaia D, Samà MT, Caputo M, Ippolito S, et al. How do etiological factors can explain the different clinical features of patients with differentiated thyroid cancer and their histopathological findings? Endocrine. 2016;56(1):129–37. CrossRefPubMed
3.
Hu J, Yuan IJ, Mirshahidi S, Simental A, Lee SC, Yuan X. Thyroid carcinoma: phenotypic features, underlying biology and potential relevance for Targeting Therapy. Int J Mol Sci. 2021;22(4):2442. CrossRef
4.
Ng M, Fleming T, Robinson M, Thomson B, Gakidou E. Global, regional, and National prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. The Lancet. 2014;384(9945):766–81.CrossRef
5.
Marcello MA, Sampaio AC, Geloneze B, Vasques ACJ, Assumpção LVM, Ward LS. Obesity and excess protein and carbohydrate consumption are risk factors for thyroid Cancer. Nutr Cancer. 2012;64(8):1190–5.CrossRefPubMed
6.
Damsgaard CT, Michaelsen KF, Molbo D, Mortensen EL, Sørensen T. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377.CrossRef
7.
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.
8.
9.
Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev. 2016;16(12):1042–54.CrossRef
10.
Grani G, Lamartina L, Montesano T, Ronga G, Maggisano V, Falcone R, et al. Lack of association between obesity and aggressiveness of differentiated thyroid cancer. J Endocrinol Invest. 2018;42(1):85–90.CrossRefPubMed
11.
Farfel A, Kark JD, Derazne E, Tzur D, Barchana M, Lazar L, et al. Predictors for thyroid carcinoma in Israel: a national cohort of 1,624,310 adolescents followed for up to 40 years. Thyroid. 2014;24(6):987–93.CrossRefPubMed
12.
Malone JI, Hansen BC. Does obesity cause type 2 diabetes Mellitus (T2DM)? Or is it the opposite? Pediatr Diabetes. 2019;20(1):5–9.CrossRefPubMed
13.
Scappaticcio L, Maiorino MI, Bellastella G, Giugliano D, Esposito K. Insights into the relationships between Diabetes, prediabetes, and cancer. Endocrine. 2016;56(2):231–9.CrossRefPubMed
14.
Chen ST, Hsueh C, Chiou WK, Lin JD. Disease-Specific Mortality and Secondary Primary Cancer in Well-Differentiated Thyroid Cancer with Type 2 Diabetes Mellitus. Plos One. 2013;8:e55179.CrossRefPubMedPubMedCentral
15.
Duran AO, Anil C, Gursoy A, Nar A, Altundag O, Tutuncu NB. The relationship between glucose metabolism disorders and malignant thyroid Disease. Int J Clin Oncol. 2013;18(4):585–9.CrossRefPubMed
16.
Balkan F, Onal ED, Usluogullari A, Tuzun D, Ozdemir D. “Is there any association between insulin resistance and thyroid cancer?: a case control study.” Endocrine. 2014;45(1):55–60.CrossRefPubMed
17.
Predictive value of. Body mass index and waist circumference for metabolic syndrome in 6-12-year-olds. Acta Paediatr. 2011;100(5):722–7.CrossRef
18.
American Diabetes A. 2. Classification and diagnosis of Diabetes: standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–28.
19.
Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2013;123(3):372–81.CrossRef
20.
Ogden CL, Carroll M, Flegal KM. Prevalence of obesity in the United States. JAMA. 2014;312(2):189–90.CrossRefPubMed
21.
Xu L, Port M, Landi S, Gemignani F, Cipollini M, Elisei R, et al. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid. 2014;24(6):966–74.CrossRefPubMedPubMedCentral
22.
B Mt ADAGR. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies - ScienceDirect. Lancet. 2008;371(9612):569–78.CrossRef
23.
Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest. 2012;35(6 Suppl):3–9.PubMed
24.
Kwon JC, Little MP, Lubin JH, Brenner AV, Wells SA, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276–85.
25.
Giovanella L, Scappaticcio L. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2019;63(3):229.PubMed
26.
Davies L, Morris L, Haymart M, Chen AY, Goldenberg D, Morris J, et al. American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: the increasing incidence of thyroid cancer. Endocr Pract. 2015;21(6):686–96.CrossRefPubMedPubMedCentral
27.
Kitahara CM, McCullough ML, Franceschi S, Rinaldi S, Wolk A, Neta G, et al. Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. Thyroid. 2016;26(2):306–18.
28.
Theurich S. Obesity and Cancer Risk. Geburtshilfe Frauenheilkd. 2017;77(3):227–9.
29.
Pinheiro-Castro N, Silva LBAR, Ong TP. Nutrition and Cancer Prevention. In: Ong TP, Moreno FS, editors. The Royal Society of Chemistry. 2019. p. 147–159.
30.
Sari R, Balci MK, Altunbas H, Karayalcin U. The effect of body weight and weight loss on thyroid Volume and function in obese women. Clinical Endocrinology. 2003;59:258.CrossRefPubMed
31.
Changxue L, Li Z, Hao Y, Willingham MC, Sheue-Yann C. Growth activation alone is not sufficient to cause metastatic thyroid Cancer in a mouse model of follicular thyroid carcinoma. Endocrinology. 2010;151(4):1929.CrossRef
32.
Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49(5):945.CrossRefPubMed
33.
Hursting SD, Lashinger LM, et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Clin Endocrinol Metabol. 2008;22(4):659–69.
34.
Cunha LL, Marcello MA, Ward LS. The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocr Relat Cancer. 2014;21(3):R85–103.
35.
Kavanagh ME, O’Sullivan KE, O’Hanlon C, O’Sullivan JN, Lysaght J, Reynolds JV. The esophagitis to adenocarcinoma sequence; the role of inflammation. Cancer Lett. 2014;345(2):182–9.CrossRefPubMed
36.
37.
Cléro é, Leux C, Brindel P, Truong T, Anger A, Teinturier C, et al. Pooled Analysis of Two Case-Control Studies in New Caledonia and French Polynesia of Body Mass Index and differentiated thyroid Cancer: the importance of body surface area. Thyroid. 2010;20(11):1285–93.CrossRefPubMed
38.
Xhaard C, de Vathaire F, Cléro E, Maillard S, Ren Y, Borson-Chazot F, et al. Anthropometric Risk Factors for Differentiated Thyroid Cancer in Young Men and Women From Eastern France: A Case-Control Study. Am J Epidemiol. 2015;182(3):202–14.
39.
40.
Duran OA, Anil C, Gursoy A, et al. The relationship between glucose metabolism disorders and malignant thyroid Disease. International Journal of Clinical Oncology. 2013;18:585–9.CrossRefPubMed
41.
Grimmichova T, Haluzik M, Vondra K, Matucha P, Hill M. Relations of prediabetes and type 2 diabetes to the thyroid cancer. Endocrine Connections. 2020;9(7):607.CrossRefPubMedPubMedCentral
42.
Li C, Kuang J, Zhao Y, Sun H, Guan H. Effect of type 2 diabetes and antihyperglycemic drug therapy on signs of tumor invasion in papillary thyroid cancer. Endocrine. 2020;69(7715):92.CrossRefPubMed
43.
Jang EK, Kim WG, Kwon H, Choi YM, Jeon MJ, Kim TY, et al. Metformin is Associated with a favorable outcome in Diabetic patients with cervical lymph node Metastasis of differentiated thyroid Cancer. Eur Thyroid J. 2015;4(3):181–8.CrossRefPubMedPubMedCentral
44.
45.
Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of Diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical characteristics and therapeutic response of differentiated thyroid carcinoma with obesity and diabetes
Authors
Xuan Wang
Yang Yu
Yanhui Ji
Ziyu Ma
Jian Tan
Qiang Jia
Ning Li
Wei Zheng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11591-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma

Research

Notch3 signaling promotes colorectal tumor growth by enhancing immunosuppressive cells infiltration in the microenvironment

Research

MicroRNA-191 regulates oral squamous cell carcinoma cells growth by targeting PLCD1 via the Wnt/β-catenin signaling pathway

Research

Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer

Correction

Correction: Exploring the prognostic significance of PKCε variants in cervical cancer

Research

Association between surgical extent and recurrence in unilateral intermediate- to high-risk papillary thyroid cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits